Untreated Myeloma

UARK 2006-66
Total Therapy 3 B: An Extension of UARK 2003-33 Total Therapy 3: A Phase II Study Incorporating Bone Marrow Microenvironment (ME)—Co-Targeting Bortezomib into Tandem Melphalan-Based Autotransplants with DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

UARK 2003-26 (High Risk Myeloma)
A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DT PACE Chemotherapy and Autologous Transplant in Multiple Myeloma

SWOG 0232
"Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Newly Diagnosed Multiple Myeloma"

SWOG 0204
Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients

SWOG 0115
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study

Back to top

Previously Treated Myeloma

(1) Regardless of prior transplant or no prior transplant

UARK 2006-28
Human Cord Blood Transplantation in Advanced Hematological Malignancies

UARK 2003-26 (High Risk Myeloma)
A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DT PACE Chemotherapy and Autologous Transplant in Multiple Myeloma

UARK 2003-18
A Phase II Study of KIR-ligand Mismatched Natural Killer Cells Transfused before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma

SWOG 0417
"A Phase II Study of Bortezomib (Velcade™, PS- 341), Thalidomide, and Dexamethasone in Patients with Refractory Multiple Myeloma"

Back to top

Previously Treated Myeloma

(2) No prior transplant only

UARK 2006-15
A Phase III Randomized Study of Tandem Transplants with or without Bortezomib (Velcade) and Thalidomide (thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients

SWOG 0115
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study

Back to top

Previously Treated Myeloma

(3) Prior transplant only

SWOG 0120
A Prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasma Proliferative Disorders

Back to top

SWOG 0340
A Prospective Observational Study of Patients with Solitary Plasmacytoma using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan

SWOG 0115
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)

UARK 2005-38
Provision of Tocilizumab for Patients with Multicentric Castleman’s Disease who have Demonstrated Benefit from Previous Tocilizumab Treatment.

UARK 2004-23
A Phase I Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects with B-cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease

Back to top

UARK 2006-21
A Single-Center, Open-Label, Randomized, Phase 1B Study Evaluating the Safety
and Tolerability of Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL) in the Treatment of Patients with Multiple Myeloma Receiving Melphalan-Based High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant